Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

April 6, 2018 updated by: Puma Biotechnology, Inc.

A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer

The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

172

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Villejuif, France, 94805
        • Institut Gustave Roussy
  • Hungary
      • Budapest, Hungary, H-1529
        • Orszagos Koranyi TBC es Pulmonologiai Intezet
      • Debrecen, Hungary, H-4012
        • University of Debrecen
  • Poland
      • Gdansk, Poland, 80-952
        • Akademia Medyczna W Gdansku
      • Otwock, Poland, 05-400
        • Mazowieckie Centrum Leczenia chorób Płuc i Gruźlicy
      • Poznan, Poland, 60-569
        • Wielkopolskie Centrum Chorób Płuc i Gruźlicy
      • Wrocław, Poland, 54-439
        • Dolnośląskie Centrum Chorób Płuc we Wrocławiu
  • Spain
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
        • Hospital Germans Trias I Puyol
  • United States
    • California
      • Los Angeles, California, United States, 90033
        • USC Norris Comprehensive Cancer Center
    • Illinois
      • Zion, Illinois, United States, 60099
        • Midwestern Regional Medical Center
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital, Yawkey Center for Outpatient Care
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • University of Minnesota
    • New York
      • New York, New York, United States, 10021
        • Memorial Sloan-Kettering
    • North Carolina
      • Charlotte, North Carolina, United States, 28203
        • Carolinas Hematology-Oncology Associates
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic
      • Cleveland, Ohio, United States, 44106
        • Case Western Reserve University
    • Tennessee
      • Nashville, Tennessee, United States, 37232-6868
        • Vanderbilt University Medical Center
    • Washington
      • Seattle, Washington, United States, 98109
        • Seattle Cancer Care Alliance
      • Seattle, Washington, United States, 98104
        • Swedish Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Pathologic diagnosis of NSCLC and current stage IIIB (with pleural effusion) or IV, not curable with conventional therapy. For Arm C, less than or equal to 20 pack-years smoking history and current non smoker. A pack year = number of packs of cigarettes smoked per day x years smoked.
  • Progression following at least 12 weeks of treatment with Tarceva or Iressa. (Arms A and B only)
  • ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2 (not declining within past 2 weeks).
  • Tumor sample available and adequate for analysis.
  • At least one measurable target lesion.
  • Adequate cardiac, kidney, and liver function
  • Adequate blood counts

Exclusion Criteria:

  • More than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic disease.
  • Significant cardiac disease or dysfunction.
  • Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2.
  • Active central nervous system metastases, as indicated by clinical symptoms and/or progressive growth.
  • Use of Tarceva or Iressa within 14 days of treatment day 1 (Arms A and B only).
  • Major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer therapy within 3 weeks of treatment day 1.
  • Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom.
  • Inability or unwillingness to swallow HKI-272 capsules.
  • Pregnant or breastfeeding women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prior Tarceva or Iressa With EGFR Mutation
HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
Drug: HKI-272
320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Other Names:
  • Neratinib
Experimental: Prior Tarceva or Iressa w/o EGFR Mutation
HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
Drug: HKI-272
320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Other Names:
  • Neratinib
Experimental: No Prior EGFR Tyrosine Kinase Inhibitor Treatment
HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, < or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
Drug: HKI-272
320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Other Names:
  • Neratinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate for Neratinib in Patients With Non-small Cell Lung Cancer
Time Frame: From first dose date to progression/death or last tumor assessment, up to three years.
Objective response rate as reported by Independent Assessment (radiographic review by independent radiologists) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions.
From first dose date to progression/death or last tumor assessment, up to three years.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Benefit Rate for Neratinib in Patients With Non-small Cell Lung Cancer
Time Frame: From first dose date to progression/death or last tumor assessment, up to three years.
Clinical benefit rate is the percentage of patients with Partial or Complete Response, or with Stable Disease >= 12 Weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
From first dose date to progression/death or last tumor assessment, up to three years.
Duration of Response for Neratinib in Patients With Non-small Cell Lung Cancer
Time Frame: From start date of response to first PD, assessed up to three years after the first randomization.
Measured from the time at which measurement criteria were first met for CR or PR (whichever status was recorded first), until the date of first recurrence, PD, or death was objectively documented, taking as a reference for PD the smallest measurements recorded since enrollment, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions.
From start date of response to first PD, assessed up to three years after the first randomization.
Progression Free Survival for Neratinib in Patients With Non-small Cell Lung Cancer
Time Frame: From first dose date to progression/death, assessed up to three years.
Defined as the interval from the date of randomization until the first date on which recurrence or progression, or death due to any cause, is documented, censored at the last assessable evaluation or at the initiation of new anticancer therapy. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v 1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
From first dose date to progression/death, assessed up to three years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Puma Biotechnology, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2005

Primary Completion (Actual)

January 1, 2009

Study Completion (Actual)

January 1, 2009

Study Registration Dates

First Submitted

December 16, 2005

First Submitted That Met QC Criteria

December 16, 2005

First Posted (Estimate)

December 19, 2005

Study Record Updates

Last Update Posted (Actual)

April 13, 2018

Last Update Submitted That Met QC Criteria

April 6, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 3144A1-200
  • B1891037

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Clinical Trials on HKI-272

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe